Combo Regimen May Improve Pathologic Complete Response Rate in TNBC in Early Ph 2 INVINCIBLE-4 of INT230-6 March 17, 2026
FAILED TRIAL: persevERA Breast Cancer study of giredestrant-palbociclib combo did not meet the primary objective of statistically significant PFS improvement in ER+ve, HER2-neg locally advanced or metastatic breast cancer March 10, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Ph 2 Results March 10, 2026
Positive Ph 3 Results from SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Announced March 10, 2026
FAILED TRIAL: Ph 3 Study of XOSPATA™ (gilteritinib) Did not Meet Primary Endpoint of OS in Patients with Newly Diagnosed FLT3m+ AML March 10, 2026
Full results from Ph 2 CHOPIN trial of percutaneous hepatic perfusion, ipilimumab, and nivolumab combo in metastatic uveal melanoma published in The Lancet Oncology March 10, 2026
Ph 2 SKNJCT-003 Trial Reported 73% Clinical Clearance and 40% Histological Clearance (CR) with D-MNA in BCC March 10, 2026
Encouraging results for 225Ac-PSMA-Trillium in advanced metastatic prostate cancer reported March 3, 2026
Positive Ph 3 Interim Topline Results for izalontamab brengitecan (Iza-bren) in Unresectable Locally Advanced or Metastatic 1L TNBC Highlighted March 3, 2026
OS Primary Endpoint Met in Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer March 3, 2026
Randomized Ph 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer March 3, 2026
New real‑world data reinforce earlier use of Pluvicto before chemotherapy in metastatic CRPC March 3, 2026
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive NMIBC March 3, 2026
Early study results show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer March 3, 2026
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC March 3, 2026
Perioperative KEYTRUDA + Padcev Reduced Risk of EFS Events by 47% and Risk of Death by 35% for Cisplatin-Eligible MIBC Patients March 3, 2026
KEYTRUDA + Paclitaxel +/- Bevacizumab Significantly Improved OS vs Paclitaxel +/- Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer March 3, 2026
WELIREG + LENVIMA Reduced the Risk of Disease Progression or Death by 30% vs Cabozantinib in Certain Previously Treated Patients With Advanced RCC March 3, 2026
Adjuvant KEYTRUDA + WELIREG Reduced the Risk of Disease Recurrence or Death by 28% vs KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage RCC March 3, 2026
Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ NSCLC in New Results from the eNRGy Trial February 25, 2026
First Interim Analysis in the Global Phase 3 FIERCE-HN Study of ficlatuzumab Completed February 25, 2026
